Status: Recruiting
Safety and Efficacy of SC101 Via Perirenal Fat Injection for Resistant Hypertension in Patients With Moderate to Severe Chronic Kidney Disease
This is a single-center, open-label, exploratory clinical study designed to evaluate the safety and efficacy of a single-session injection of SC101, a small interfering RNA (siRNA) agent, into the perirenal fat. This study plans to enroll 3 participants, aged 18 to 65 years, who have a clinical diagnosis of resistant hypertension and moderate to severe chronic kidney disease (CKD).
Participants needed: 3
Trial details
Phase: Phase 1Age: 18-65Biological sex: AllType: InterventionalSponsor: The First Affiliated Hospital with Nanjing Medical UniversityUpdated: Apr 1, 2026Locations: 1
Eligibility criteria
Age ≥ 18 and ≤ 65 years. [+6]
Obvious pseudo-resistant hypertension caused by white-coat effect, incorrect BP... [+19]